- Home
- GMAB vs INSM Comparison
GMAB vs INSM Comparison
Compare GMAB & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- INSM
- Stock Information
- Founded
- GMAB 1999
- INSM 1988
- Country
- GMAB Denmark
- INSM United States
- Employees
- GMAB N/A
- INSM N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- GMAB Health Care
- INSM Health Care
- Exchange
- GMAB Nasdaq
- INSM Nasdaq
- Market Cap
- GMAB 15.0B
- INSM 12.5B
- IPO Year
- GMAB N/A
- INSM 2000
- Fundamental
- Price
- GMAB $20.45
- INSM $72.67
- Analyst Decision
- GMAB Buy
- INSM Strong Buy
- Analyst Count
- GMAB 8
- INSM 16
- Target Price
- GMAB $43.00
- INSM $83.64
- AVG Volume (30 Days)
- GMAB 1.5M
- INSM 1.6M
- Earning Date
- GMAB 11-06-2024
- INSM 10-31-2024
- Dividend Yield
- GMAB N/A
- INSM N/A
- EPS Growth
- GMAB 14.35
- INSM N/A
- EPS
- GMAB 10.80
- INSM N/A
- Revenue
- GMAB $2,967,926,227.00
- INSM $342,958,000.00
- Revenue This Year
- GMAB $30.31
- INSM $18.96
- Revenue Next Year
- GMAB $16.49
- INSM $41.96
- P/E Ratio
- GMAB $18.39
- INSM N/A
- Revenue Growth
- GMAB 17.75
- INSM 22.13
- 52 Week Low
- GMAB $20.37
- INSM $21.92
- 52 Week High
- GMAB $32.88
- INSM $80.53
- Technical
- Relative Strength Index (RSI)
- GMAB 25.28
- INSM 53.20
- Support Level
- GMAB $20.50
- INSM $64.86
- Resistance Level
- GMAB $23.47
- INSM $74.32
- Average True Range (ATR)
- GMAB 0.45
- INSM 3.07
- MACD
- GMAB -0.18
- INSM 0.22
- Stochastic Oscillator
- GMAB 2.74
- INSM 82.56
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.